Start Time: 16:30 January 1, 0000 5:18 PM ET
Myriad Genetics, Inc. (NASDAQ:MYGN)
Q1 2023 Earnings Conference Call
May 03, 2023, 16:30 PM ET
Company Participants
Paul Diaz - President and CEO
Nicole Lambert - COO
Bryan Riggsbee - CFO
Mark Verratti - Chief Commercial Officer.
Matthew Scalo - SVP, IR
Conference Call Participants
Andrew Cooper - Raymond James
Dave Delahunt - Goldman Sachs
John Kim - Bank of America
Jack Meehan - Nephron Research
Puneet Souda - SVB
Jacob Krahenbuhl - Stephens
Matthew Scalo
Okay. Good afternoon, and welcome to the Myriad Genetics' First Quarter 2023 Earnings Call. During the call, we will review the financial results we released today. And afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our Web site at investor.myriad.com.
I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Paul Diaz, our President and Chief Executive Officer; Bryan Riggsbee, our Chief Financial Officer; Nicole Lambert, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer.
This call can be heard live via webcast at investor.myriad.com. And a recording will be archived in the Investors section of our Web site along with this slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events, or the future financial performance of the company.
These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections are forward-looking statements.
With that, I will now turn the call over to Paul.
Paul Diaz
Good afternoon, everyone, and thank you for joining us. On today's call, we will discuss highlights from the first quarter and provide updates on the strategic initiatives that are driving our long-term growth plan. So many positive changes happening across our organization.
I want to take a minute to thank our Myriad teammates and our provider partners for their continued commitment to advancing our mission and vision to make genetic testing and precision medicine more accessible, helping people take more control of their health and to enable providers to better treat and prevent disease.